ClinicalTrials.gg
RecruitingNCT07158164Updated Nov 13, 2025

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

A Phase 4 interventional study of Fluorouracil injection and Xeloda in Colorectal Neoplasms, Breast Neoplasms and Head and Neck Neoplasms, sponsored by Rutgers, The State University of New Jersey. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Rutgers, The State University of New Jersey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.

Planned enrollment
50th of 132
100 · median 66
Started
2025
with 3 others
Phase 4
5 of 159
1 open now
Primary completion
2027-07
later than 11 of 18 live
Registered
158th of 159
by date

Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is the 50th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 4, reaches primary completion later than 11 of the 18 other live ones, and was the 158th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies testing fluorouracil in Colorectal Neoplasms, or all of them as a file.
02

Study summary

To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.

Read the detailed description

Fluropyrimidines (FPs), such as 5-Fluorouracil (5-FU) and Capecitabine, are cornerstone chemotherapy agents widely used in the treatment of various cancers, including gastrointestinal, head and neck, and breast cancers. Dosing of FP, specifically 5-FU, has been a challenge since this drug was first synthesized in 1957 by Charles Heidelberger1. 5FU had been given on numerous schedules and doses, including weekly 24 hr infusion, 48-hour infusion every two weeks, and daily five-times-a-day infusion with leucovorin (Mayo Regimen) and weekly bolus with leucovorin infusion (Roswell, Park Regimen). In addition, oral fluropyrimidines, including Capecitabine, Tegafur, and S-1, are widely used throughout the world and have more prolonged dosing schedules, typically consisting of 2- to 3-week courses given twice daily. Despite their efficacy, the administration of these therapies has historically been challenging due to significant inter-patient variability in toxicity. A small but critical proportion of patients experience severe, potentially fatal toxicities, primarily attributed to a deficiency in Dihydropyrimidine Dehydrogenase (DPD) enzyme.

DPD is the key enzyme in the catabolism of 5-FU, metabolizing it into less toxic metabolites, such as FBAL. DPD activity may also be involved in decreasing the absorption of 5FU from the oral GI tract and accounts for its variability in absorption. When using irreversible DPD inhibitors, such as ethinyl-uracil, the daily oral dose of 5FU was less than 2 mg/m² compared to more than 1000 mg/m² when given orally.

Genetic variants in the DPYD gene, which encodes the DPD enzyme, are responsible for reduced or absent enzyme function. These variants are catalogued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and range from no function to reduced or normal function. While the prevalence of any DPYD reduced activity variant is estimated at 2-4% in the American population (heterozygous abnormality), homozygous abnormalities are much rarer (\<0.0025%).

Historically, routine DPYD gene testing has not been widely recommended in the United States due to concerns about cost, treatment delays, and inconvenience2. However, the European community, with a higher incidence of DPYD deficiency and more affordable testing, has recommended routine testing for some time. However, the FDA only recently added a black box warning against using 5-FU in patients with DPD enzyme deficiency. On January 24, 2025, the FDA, as part of Project Renewal, recommended that clinicians consider testing all patients and discuss the issue with them. The FDA notes that for complete DPD deficiency, no dose is considered safe; however, for "partial deficiency," they state, "there is insufficient data to recommend a specific dose in patients with partial DPD deficiency."4

Given that the new warnings are now part of the package insert for 5-FU and Capecitabine, it is more incumbent on the practitioner to test for this abnormality for all patients beginning fluoropyrimidine therapy. CPIC has proposed reduction guidelines for patients with one gene abnormality (heterozygotes), which include a 50% dose reduction or possibly a 30% dose reduction for those with less severe DPD activity.³ However, these guidelines lack widespread clinical validation, raising questions about their necessity for toxicity control versus potential underdosing of such patients, affecting therapeutic outcomes. This prospective interventional treatment study aims to validate these DPYD-guided dosing strategies in a real-world clinical setting

03

Conditions studied

  • Colorectal Neoplasms
  • Breast Neoplasms
  • Head and Neck Neoplasms
  • Gastro-Intestinal Intraepithelial Neoplasia

Keywords

  • colorectal cancer
  • breast cancer
  • head and neck cancer
  • Gastro-Intestinal cancer
  • chemotherapy toxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of cancer in either the or setting requiring initial therapy with 5-FU or Capecitabine.
  • DPYD testing performed by a CLIA-certified laboratory (i.e., Guardant 360 or Caris blood testing for genomic profiling, DPYD testing by the Mayo Clinic or other certified laboratory) with results available before starting chemotherapy.
  • DPYD testing results falling into one of the following cohorts for therapy with a fluoropyridine:
  • Study Cohort: Patients with one DPYD variant in one gene (heterozygotes).
  • Control Arm: Patients with normal or wild-type DPYD genes, for comparison, will be treated at the usual 100% dose.

    --FOLFOX regimen (N=50)

  • Performance Status 0-2.
  • or non-measurable disease allowed, including adjuvant 5-FU-based regimens.

Exclusion criteria

Exclusion Criteria:

  • Patients for whom 5-FU or Capecitabine therapy is or not deemed appropriate in the judgment of the treating physician.
  • Patients with two DPYD variants (homozygous deletions or non-functional genetic variants, or double heterozygotes with two different abnormalities) should not receive 5-FU or Capecitabine and are therefore excluded from the study.
  • Pregnant Women and Children
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Normal DPYD Patients (Control Arm)

    Should receive 100% of the standard recommended doses as per the BEACON order plan. Dose Reduction for Toxicity: Reduce doses by 25% for unacceptable Grade 3 or any Grade 4 toxicity or clinically significant laboratory anbormaillity. If this occurs again, an additional 25% reduction (to 50% of the initial doses) should be used.

    Drug: Fluorouracil injection · Drug: Xeloda

  • Experimental
    Patients with One DPYD Variant (Heterozygotes)

    Will receive 50% of the regular starting doses for the first two cycles. For example, for FOLFOX or FOLFIRI, the 5FU bolus would be 200 mg/m², and the infusion would be 46 hours at 1200 mg/m².

    Drug: Fluorouracil injection · Drug: Xeloda

Interventions

06

What researchers measure

Primary outcomes

  1. incidence of severe fluoropyrimidine-related toxicities (Grade 3-5)

    Number and proportion of patients experiencing Grade 3, 4, or 5 toxicities related to 5-FU or Capecitabine, as defined by CTCAE v5.0.

    Time frame: up to 24 months

Secondary outcomes

  1. Patterns of Dose Modification (Reductions and Escalations)

    Number and type of dose modifications (reductions, escalations, discontinuations) in each arm,

    Time frame: up to 24 months

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Of 38 phase 4 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 57. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Jul 7, 2027
CompletionEst.
Jul 7, 2029
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158164
Responsible party
Howard S. Hochster, MD (Distinguished Professor of Medicine, Director Clinical Oncology Research, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Sep 5, 2025
Start date
Aug 27, 2025
Primary completion
Jul 7, 2027 (estimated)
Completion
Jul 7, 2029 (estimated)
Last update
Nov 13, 2025

Study contacts

Howard S Hochster, MD
Contact
howard.hochster@rutgers.edu
732-253-5618
Christian F Misdary
Contact
cm1344@cinj.rutgers.edu
732-253-5618
Howard S. Hochster, MD
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Capecitabine

Start the discussion